| Identification | More | [Name]
Prazosin hydrochloride | [CAS]
19237-84-4 | [Synonyms]
1-(3-AMINO-6,7-DIMETHOXY-2-QUINAZOLINY)-4-(2-FURANYLCARBONYL)PIPERAZINE
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(2-FURANYLCARBONYL)PIPERAZINE HYDROCHLORIDE
FURAZOSIN HYDROCHLORIDE
PRAZOSIN HCL
PRAZOSIN HYDROCHLORIDE
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazinehydr
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazinemonohydrochlo
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-piperazinmonohydro
2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazolinehydrochloride
4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-quinazolinhydrochlori
cp-12299-1
deprazolin
hypovase
hypovasole
peripress
pratsiol
prazosinclorhidrato
sinetens
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride
PRAZOSIN HYDROCHLORIDE USP | [EINECS(EC#)]
242-903-4 | [Molecular Formula]
C19H22ClN5O4 | [MDL Number]
MFCD00058177 | [Molecular Weight]
419.86 | [MOL File]
19237-84-4.mol |
| Chemical Properties | Back Directory | [Appearance]
Off-White to Yellow Powder | [Melting point ]
277 - 280 °C
| [storage temp. ]
2-8°C | [solubility ]
H2O: 1 mg/mL, clear, colorless
| [form ]
solid
| [color ]
white
| [Water Solubility ]
Soluble in dimethyl sulfoxide, ethanol, water, methanol. | [Usage]
An antihypertensive. | [Merck ]
7717 | [BRN ]
4303561 | [InChIKey]
WFXFYZULCQKPIP-UHFFFAOYSA-N | [CAS DataBase Reference]
19237-84-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed.
R36/37/38:Irritating to eyes, respiratory system and skin .
R62:Possible risk of impaired fertility. | [Safety Statements ]
S28:After contact with skin, wash immediately with plenty of ... (to be specified by the manufacturer) .
S36:Wear suitable protective clothing . | [RIDADR ]
3249 | [WGK Germany ]
3
| [RTECS ]
VA1350000
| [F ]
10 | [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
2934990002 | [Hazardous Substances Data]
19237-84-4(Hazardous Substances Data) | [Toxicity]
dog,LD50,oral,> 700mg/kg (700mg/kg),GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDSKIDNEY, URETER, AND BLADDER: OTHER CHANGES GASTROINTESTINAL: NAUSEA OR VOMITING,Oyo Yakuri. Pharmacometrics. Vol. 17, Pg. 39, 1979. |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White to Yellow Powder | [Originator]
Hypovase, Pfizer, UK,1974 | [Uses]
An antihypertensive. α1-Adrenergic blocker. | [Manufacturing Process]
Preparation of 2-Chloro-4-Amino-6,7-Dimethoxyquinazoline: To 800 ml of a solution of anhydrous ammonia in tetrahydrofuran at room temperature is added 30 g of 2,4-dichloro-6,7-dimethoxyquinazoline [F.H.S. Curd et al., J. Chem. Soc., p 1759 (1948)]. The mixture is stirred for 44 hours. The precipitate (29 g, MP 267° to 268°C) is filtered and recrystallized from methanol to yield 19 g of 2-chloro-4-amino-6,7-dimethoxyquinazoline, MP 302°C (dec.).
Preparation of 2-(1-Piperazinyl)-4-Amino-6,7-Dimethoxyquinazoline: To 5 g of 2-chloro-4-amino-6,7-dimethoxyquinazoline, is added 20 g of a 25% solution of piperazine in ethanol. The mixture is heated at 160°C for 16 hours in a pressure bottle. The solvent is then evaporated and the residue is recrystallized from methanol/water.
Preparation of 2[4-(2-Furoyl)-Piperazinyl]-4-Amino-6,7-Dimethoxyquinazoline: To 0.10 mol 2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline in 300 ml methanol is added with vigorous stirring, 0.10 mol 2-furoyl chloride. After addition is complete, the mixture is stirred for 3 hours at room temperature. The solids are filtered to give the desired product, MP 278° to 280°C. | [Brand name]
Minipress
(Pfizer). | [Therapeutic Function]
Antihypertensive | [General Description]
The antihypertensive effectsof prazosin hydrochloride, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride(Minipress), are caused by peripheral vasodilation as a resultof its blockade of 1-adrenergic receptors. In ligand-bindingstudies, prazosin hydrochloride has 5,000-fold greater affinityfor α1-receptors than for some α2-adrenergic receptors. | [Biological Activity]
α 1 and α 2B -adrenoceptor antagonist. Also a potent antagonist at the melatonin MT 3 receptor (K i = 10.2 nM). Also available as part of the α 1 -Adrenoceptor Tocriset™ and Mixed Adrenergic Tocriset™ . | [Biochem/physiol Actions]
Peripheral α1-adrenoceptor antagonist; vasodilator. Prazosin can be used to treat chronic posttraumatic stress disorder (PTSD). It plays a role in reducing blood pressure by relaxing blood vessels, hence used in the treatment of high blood pressure. | [Clinical Use]
Prazosin hydrochloride is readily absorbed, and plasmaconcentrations reach a peak about 3 hours after administration.Plasma half-life is between 2 and 3 hours. Prazosin hydrochlorideis highly bound to plasma protein; it does notcause adverse reactions, however, with drugs that might bedisplaced from their protein-binding sites (e.g., cardiac glycosides).It may cause severe orthostatic hypertension becauseof its -adrenergic blocking action, which preventsthe reflex venous constriction that is activated when an individualsits up from a prone position. | [storage]
Room temperature | [Purification Methods]
The salt is recrystallised by dissolving it in hot MeOH, adding a small volume of MeOH/HCl (dry MeOH saturated with dry HCl gas) followed by dry Et2O until crystallisation is complete. Dry it in vacuo over solid KOH till the odour of HCl is absent. It has been recrystallised from hot H2O, the crystals are washed with H2O, and the H2O is removed azeotropically with CH2Cl2, and dried in a vacuum. [NMR and IR: Honkanen et al. J Heterocycl Chem 17 797 1980, cf Armarego & Reece Aust J Chem 34 1561 1981.] It is an antihypertensive drug and is an 1-adrenergic antagonist [Brosman et al. Proc Natl Acad Sci USA 82 5915 1985]. |
|
|